-
Product Insights
Galena Complex Mine
The Galena Complex Mine is a lead mine in United States. It is currently in operation. Empower your strategies with our Galena Complex Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy...
-
Product Insights
Abra Base Metals Project
The Abra Base Metals Project is a lead mine in Australia. It is currently in operation. Empower your strategies with our Abra Base Metals Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to...
-
Product Insights
Galena Park refinery, United States
Galena Park refinery is located in Texas, United States. It started operations in 2015. The refinery is operated by Kinder Morgan Energy Partners LP. Empower your strategies with our Galena Park refinery, United States report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or...
-
Product Insights
Buzz Oates – 8336 Galena Ave Warehouse Development – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our Buzz Oates - 8336 Galena Ave Warehouse Development - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...
-
Product Insights
Essential Thrombocythemia Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Essential Thrombocythemia Global Clinical Trials Review, H2, 2017" provides an overview of Essential Thrombocythemia clinical trials scenario. This report provides top line data relating to the clinical trials on Essential Thrombocythemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Pharmapoint: HER2-Positive Breast Cancer – Global Drug Forecast and Market Analysis to 2025
HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established disease management strategies using numerous combinations of chemotherapy with Herceptin, Perjeta, and the tyrosine kinase inhibitor (TKI) Tykerb (lapatinib). During the forecast period from 2015–2025, GlobalData expects that the HER2-positive market will grow due to the launch of HER2-targeted agents in the early disease setting and...
-
Sector Analysis
Immuno-Oncology Strategic Insight: Multi-Indication and Market Size Analysis
GlobalData estimates that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint inhibitors, which will have sales of approximately $10 billion in 2019, rising to $24 billion by 2024. The highest-selling IO drugs by 2024 will be Opdivo and Keytruda, both PD-1 inhibitors, with sales of approximately $10 billion...